Skip to main content
. Author manuscript; available in PMC: 2022 Nov 2.
Published in final edited form as: Cell Stem Cell. 2020 Jan 16;26(2):187–204.e10. doi: 10.1016/j.stem.2019.11.016

Figure 4. ZIKV Infection of GSCs Requires Integrin β5.

Figure 4.

(A) Matched TCGA GBM and normal brain from the genotype-tissue expression (GTEx) dataset, showing the expression levels of selected integrins; log scale by Log2 (transcripts per million [TPM]+1). *p < 0.0001 (n = 163 samples for GBM, n = 207 samples for normal brain).

(B) mRNA expression of integrins following shRNA-mediated knockdown in two patient-derived GSCs (GSC1517 and GSC3565). Values were normalized to a non-targeting shCONT.

(C) Cell viability in GSC3565 on days 0, 3, and 5 following treatment with integrin-targeting shRNAs, ZIKV, or a combination.

(D) Quantification of the number of spheres formed by GSCs on day 5 following treatment with integrin-targeting shRNAs, ZIKV, or a combination.

(E) Representative images of spheres derived from GSC3565 (C and D). Scale bars, 100 μm.

(F) ZIKV infectivity assessed by qRT-PCR on patient-derived GSCs transduced with either shCONT or one of two non-overlapping shRNAs targeting integrin β subunits that paired with integrin αv.

Two biological replicates with three technical repeats were performed. Data presented as mean ± SEM. ****p < 0.0001 by one-way ANOVA.